Harlan Sprague Dawley has tapped the loan market for financing to back its acquisition of SafePharm. UBS leads the loans, which consist of a six-year, $30 million super-priority revolver divided between U.S. dollars and euros, and a seven-year, $330 million first-lien term loan. Pricing is LIBOR plus 2
...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.
